

Cambio constitutes the operating entities under Sanolium AB. All figures in ( ) refer to the comparable figures from previous year. The pro forma for the full year 2019 includes operating activities from January 1<sup>st</sup> to February 20<sup>th</sup>. The pro forma prior to 2019 refers to Cambio Group operating activities in periods prior to 2019.

*Revenue in the second quarter amounted to 195.8 MSEK, representing growth of 7.3%*


### Q2, April - June 2021

- Revenue amounted to 195.8 (182.4) MSEK in the second quarter, representing a growth of 7.3%
- Adjusted EBITDA amounted to 22.7 (50.6) MSEK, representing a decline of -55.1%
- Revenue recognition is negatively affected by the Covid-19 situation


### January - June 2021

- Revenue during January - June amounted to 402.5 (January - June, 2020; 360.3) MSEK
- Adjusted EBITDA amounted to 75.0 (January - June; 100.2) MSEK

### Q2, revenue



### Pro forma revenue, MSEK



### Key figures

MSEK	Q2 2021	Q2 2020	Jan-Jun 2021	Jan-Jun 2020
Revenue	195.8	182.4	402.5	360.3
Adjusted EBITDA	22.7	50.6	75.0	100.2
Adjusted EBITDA-margin	11.6%	27.7%	18.6%	27.8%
EBIT	-25.1	8.3	-11.9	17.5
Financial net	-5.8	-6.7	-9.9	-13.3
Income before tax	-30.9	1.6	-21.8	4.2
Net income	-26.9	0.7	-19.2	2.8

Sanolium AB is the parent company in the Cambio Group, since February 20, 2019. The largest operating subsidiary in that group is Cambio Healthcare Systems which was founded in 1993 to deliver comprehensive IT solutions for healthcare organizations. Today, Cambio is an e-health company providing smart, reliable and user-friendly solutions to improve healthcare and patient safety with a market leading position in the Nordics including more than 100 000 users. We are committed to improve healthcare and patient safety.

## CEO's Comments

*The increased demand for our solutions reflects the need for increased digitalization in health- and social-care. The Nordic regions and municipalities need to invest more in IT than they have done historically. Cambio has the products and services to bridge the technical gap that the regions and municipalities face, and to enable tomorrow's health- and social-care. Together with our customers we contribute to a better and healthier society.*

### About Cambio

Cambio is well positioned to become the Nordic leader within eHealth. Today we principally serve Nordic regions and municipalities by delivering their core healthcare IT system.

The constantly growing and aging population creates a need for increased productivity and efficiency in health- and social-care and in a world with limited resources this can be achieved by increased digitalization.

The growing gap between the available technologies and the technical solutions used by healthcare providers today can and will be bridged through Cambio's solutions.

### About second quarter

The continued Covid-19 situation and resulting pressure on the healthcare system means that direct interactions with our customers remain at a low level. However we continue to make progress and are focused on improving Cambio's operational efficiency and productivity.

During the second quarter the Covid-related vaccinations peaked in Sweden. MittVaccin is now an established part of the vaccination solutions market in Sweden with more than one fifth of all Covid-vaccinations carried out via the MittVaccin's solution.

Cambio is looking forward to strengthening our partnerships with our customers and in supporting those in the health- and social-care sectors to become ever more efficient.



Lars Andåker, Interim CEO

## Second quarter

Revenue in the second quarter amounted to 195.8 (182.4) MSEK, representing a growth of 7.3%. Support and maintenance fees constitute the largest share of the revenue. License revenue and Professional Services revenue are attributable to the development of the existing product as well as the Sussa project.

Adjusted EBITDA in the second quarter amounted to 22.7 (50.6) MSEK resulting in an adjusted EBITDA margin of 11.6 (27.7) %.

Employee related expenses amounted to 141.2 (110.2) MSEK, corresponding to an increase of 28.1%. The number of full-time employees rose to 765 in the second quarter, an increase of 11,6 % from the comparable figure last year. Of these 393 were employed in Sweden and 323 were women.

Depreciation and amortization amounted to 37.8 MSEK, of which 27.8 MSEK relates to amortization of intangible assets linked to M&A activities, 3.8 MSEK refers to financial leases and 5.0 MSEK refers to amortization of capitalized R&D. The remaining depreciation of tangible assets amounted to 1.2 MSEK.

Non-recurring items amounted to 10 MSEK, consisting of 3.1 MSEK relating to the introduction of a new ERP system and 6.9 MSEK relate to change of management and other.

## Significant events and outlook

No significant events to report about in the second quarter.

## Covid-19 implications on the business

Cambio provides business-critical software that many doctors and nurses in Sweden use on a daily basis to deal with healthcare matters, including the current Covid-19 pandemic. Cambio's most important task under the current circumstances is to ensure our products fulfil their purpose without any interruptions or down time.


Direct interactions with our customers remain at a low level making it harder to sell new projects and obtain delivery approvals. However we continue to make progress and are focused on improving Cambio's operational efficiency and productivity.



## Long-term outlook

The global trend of a constantly growing and aging population is driving the need to invest in health- and social-care. In a world with limited resources these areas of care face increasing pressure to become more productive and efficient, resulting in a greater demand for digitalization. A key pillar of the digital transformation is communication and in particular the way in which health- and social-care institutions interact. A solid IT infrastructure is key to the development of a future-proof way of working.

Today there is a sizeable gap between the available technologies and the technical solutions used by health- and social-care organizations. Cambio's solutions address that technology gap, resulting in a strong and sustainable demand for our offerings on a global scale.



## Liquid funds and cash conversion

At the end of the second quarter, Cambio's cash amounted to 147.3 MSEK. Additionally, Cambio has a non-utilized credit facility amounting to 100.0 MSEK.

Cambio's strong cash conversion is driven by maintenance fees invoiced one year in advance, and a low level of capital expenditure as well as capitalized R&D that has been stable over recent periods. Since most of the invoices are issued in the fourth quarter of each year, a quarterly comparison of Cambio's cash conversion does not provide a fair comparison.

Cash conversion at the end of 2020 amounted to 115.2 % (133.0 %). During the past 6 years cash conversion has been above 100.0%.

## Leverage

At the end of the first quarter the leverage amounted to 4.4 x LTM Q2-21 EBITDA. The leverage is calculated according to the table on the right. This calculation is in line with the definitions agreed in the existing bond terms.

## Balance sheet

Cambio's fixed assets amount to 85.1%, of which 82.4% refer to intangible assets subject to impairment tests. Management believes that these assets provide for a solid foundation to drive future profitability and growth.

The external interest-bearing debts amounted to 540.6 MSEK, of which 497.9 MSEK relates to an utilized bond facility and 42.7 MSEK relates to a financial lease liability under IFRS 16.

The Senior Secured 500 MSEK bond rolls with a 3-months-STIBOR + 4.25%. In order to reduce that exposure Sanolium AB has entered into an Interest Rate Cap Transaction. In conjunction to that Sanolium AB has secured the floating part of the interest on half of the bond value, 250 MSEK, to a maximum of 0.188%. The termination date of this derivative is March 2023.


## Products and technology

Cambio's vision is to enable tomorrow's healthcare today. This will be achieved in close partnership and cooperation with the regions, municipalities and private companies and with continued investments in innovation and technology to further strengthen our product offering.

### Leverage, MSEK

Liability	497.9
Financial lease K3	3.1
Cash	-147.3
80 percent of deferred income	186.6
Net debt (Liability-surplus cash)	501.0
Applicable LTM EBITDA	113.7
Leverage (Net debt/EBITDA)	4.4x

### Balance sheet



Fixed Assets	85%
Short term assets	9%
Liquid funds	6%
Equity	44%
Utilized bond facility	20%
Other liabilities	35%

Cambio COSMIC, is a healthcare information system used in university hospitals, primary care clinics and community care homes. Cambio COSMIC is built on a modern proprietary platform with a wide range of associated subsystems and modules supporting various healthcare disciplines.

Cambio VIVA is used in municipalities. It is an operating system used to coordinate the activities and processes of social services, healthcare and care professionals. VIVA's proprietary platform enables a digital working environment supporting work processes and organizational developments and changes.

In addition to these two major product categories, Cambio offers other connected services and solutions. Cambio is also preparing and planning to deliver Managed Service offering in the future.



*Cambio COSMIC health care information system. Improving the efficiency of daily tasks and patient outcomes for 100.000 users.*

## Customers

Following the newly agreed contract with the option regions within the Sussa customer group Cambio will cover 17 out of 21 regions in Sweden. This means Cambio will cover 46.3% of the Swedish population and 51.0% of the end users.

17 of 21  
regions

Today, Cambio has active users in 8 out of 21 regions in Sweden, covering 22.7% of the Swedish population and 26.0% of the end users. Cambio VIVA covers 39 out of the 290 municipalities in Sweden, covering 14.6% of the Swedish population and 12.0% of the end users.

The ambition is to increase the number of customers and to increase the depth and breadth of our product offering so that end users benefit from as much support as possible. In Denmark, Cambio offers a wide range of products and our ambition is to reach more end users with relevant offerings.

## Sustainability

Cambio's business model is built on accelerating sustainability in organizations within health- and social-care. Cambio's sustainability report is published on [www.cambiogroup.com](http://www.cambiogroup.com) under Investor Relations.



## Market and legislation

The market for delivering e-Health software services is regulated by the Medical Device Directive MDD 93/42/EEC. This regulation will be replaced in 2021 by the Medical Device Regulation MDR 2017/45.

Almost all tenders ask for a certified Quality Management System, an active Environmental work, and an active Information Security Work. Cambio has the most relevant ISO certifications for the business, such as ISO 9001, 14001, 20000 and 27001.

Most of our customers are publicly financed organizations that are subject to rules and regulations regarding public tender processes. In conjunction with this Cambio needs to be fully aware of those formal processes and act within those frameworks.

Cambio is fully compliant with GDPR and the way in which personal information is handled.

## Risks

The group's operations are exposed to a number of financial risks such as market risks (currency risk and interest risk), credit risk and liquidity risk. The group aims to minimize potential adverse effects of these risks on the group's financial performance.

The group's exposure to currency risk consists primarily of transactions taking place in foreign currencies between subsidiaries of Cambio. The company does not use derivative instruments in order to reduce currency risks at present.

Since Sanolium AB in September 2019 issued a senior secured bond for a total amount of 500 MSEK, the company is exposed to interest rate trends. The bond terms give the investors a yield of STIBOR 3M + 4.25%. In order to reduce that exposure Sanolium AB has entered into an Interest Rate Cap Transaction with DNB BANK ASA. The implication of the transaction is that Sanolium AB has secured the floating part of the interest on half of the bond value, 250 MSEK, to a maximum of 0.188%. The termination date of the derivative is 26-03-2023. The derivative is valued at fair value according to a technique based on fully observable market information.

For a more detailed description of the risks mentioned above and other risks and uncertainties, please refer to the Annual Report 2019.

## Transactions with related parties

Sanolium AB is the senior parent company in the group. Related parties consist of all subsidiaries and senior executives in the group and their Related parties. Transactions take place on market terms.

The extent and nature of transactions with related parties in the period is consistent with previous year's transactions with related parties, as described in the 2019 annual report.

This interim report has not been subject to external audit.

Stockholm, 19 August 2021

Lars Andåker

Interim CEO

## Consolidated income statement

<b>MSEK</b>	<b>Q2 2021</b>	<b>Q2 2020</b>	<b>Jan-Jun 2021</b>	<b>Jan-Jun 2020</b>
License revenue	18.7	30.2	50.5	56.3
Maintenance revenue	111.0	101.0	223.8	207.5
Professional services	44.6	38.1	92.6	71.9
Other revenue	21.5	13.1	35.6	24.6
<b>Revenue</b>	<b>195.8</b>	<b>182.4</b>	<b>402.5</b>	<b>360.3</b>
Cost of services provided	-21.7	-14.2	-38.8	-27.2
<b>Gross profit</b>	<b>174.1</b>	<b>168.2</b>	<b>363.7</b>	<b>333.1</b>
Employee related expenses	-141.2	-110.2	-268.8	-214.7
Facilities	-1.9	-1.8	-3.4	-3.8
Marketing	-0.2	-0.5	-0.7	-2.1
Travel	-0.5	-0.4	-0.7	-2.1
Other expenses	-7.6	-4.7	-15.1	-10.2
<b>Total operating expenses</b>	<b>-151.4</b>	<b>-117.6</b>	<b>-288.7</b>	<b>-232.9</b>
<b>Adjusted EBITDA</b>	<b>22.7</b>	<b>50.6</b>	<b>75.0</b>	<b>100.2</b>
Depreciation	-37.8	-35.8	-75.3	-71.8
<b>Adjusted EBIT</b>	<b>-15.1</b>	<b>14.8</b>	<b>-0.3</b>	<b>28.4</b>
Non recurring items	-10.0	-6.5	-11.6	-10.9
<b>EBIT</b>	<b>-25.1</b>	<b>8.3</b>	<b>-11.9</b>	<b>17.5</b>
Financial net	-5.8	-6.7	-9.9	-13.3
<b>Income before tax</b>	<b>-30.9</b>	<b>1.6</b>	<b>-21.8</b>	<b>4.2</b>
Tax	4.0	-0.9	2.6	-1.4
<b>Net Income</b>	<b>-26.9</b>	<b>0.7</b>	<b>-19.2</b>	<b>2.8</b>


## Consolidated statement of Comprehensive income

<b>MSEK</b>	<b>Q2 2021</b>	<b>Q2 2020</b>	<b>Jan-Jun 2021</b>	<b>Jan-Jun 2020</b>
<b>Net Income/loss</b>	<b>-26.9</b>	<b>0.7</b>	<b>-19.2</b>	<b>2.8</b>
operations	-0.3	-5.0	-1.2	-2.3
<b>Total comprehensive income for the period</b>	<b>-27.2</b>	<b>-4.3</b>	<b>-20.4</b>	<b>0.5</b>
<i>Total comprehensive income attributable to:</i>				
Equity holders of the parent company	-27.2	-4.3	-20.4	0.5
Non controlling interest	NA	NA	NA	NA



## Non-Recurring items relating to:

<b>MSEK</b>	<b>Q2 2021</b>	<b>Q2 2020</b>	<b>Jan-Jun 2021</b>	<b>Jan-Jun 2020</b>
Contribution from decided divestment		-1.7		-3.6
Advisory fees mergers and acquisitions		-0.2		-1.5
New ERP system	-3.1	-4.2	-4.2	-5.3
Other	-6.9	-0.4	-7.4	-0.5
<b>Total non-recurring items</b>	<b>-10.0</b>	<b>-6.5</b>	<b>-11.6</b>	<b>-10.9</b>



*The app Min Hälsa contains all information a patient would need in relation with healthcare.*

## Consolidated Balance Sheet

<b>MSEK</b>	<b>2021-06-30</b>	<b>2020-12-31</b>
<b>Fixed Assets</b>		
Intangible assets	2,005.4	2,049.0
Tangible assets	19.9	18.1
Right-of-use assets	41.9	50.6
Financial assets	4.8	3.2
<b>Total Fixed Assets</b>	<b>2,072.0</b>	<b>2,120.9</b>
<b>Current Assets</b>		
Inventory	0.1	0.3
Work in progress	104.1	55.7
Accounts receivables	64.8	76.4
Other receivables	14.6	6.0
Tax receivables		8.9
Prepaid expenses, accrued income	31.4	17.3
Cash	147.3	398.5
<b>Total Current Assets</b>	<b>362.3</b>	<b>563.1</b>
<b>Total Assets</b>	<b>2,434.3</b>	<b>2,684.0</b>
<b>Equity</b>		
Share capital	1.7	1.7
Non-restricted equity	1,098.2	1,143.5
Net income for the period	-19.2	-44.1
<b>Total Equity</b>	<b>1,080.7</b>	<b>1,101.1</b>
<b>Provisions</b>	<b>17.1</b>	<b>15.3</b>
<b>Total Financial Liabilities</b>	<b>497.9</b>	<b>497.6</b>
<b>Other liabilities</b>		
Advance payments	5.1	32.5
Accounts payable	14.1	15.0
Lease liabilities	42.7	51.1
Deferred/ Current Tax liabilities	324.6	337.5
Other liabilities	130.0	140.9
Accrued expenses	88.9	80.6
Deferred income	233.2	412.4
Total Other Liabilities	838.6	1,070.0
<b>Total Equity and Liabilities</b>	<b>2,434.3</b>	<b>2,684.0</b>

## Changes in group equity

<b>MSEK</b>	<b>Jan-Jun 2021</b>	<b>Jan-Jun 2020</b>
Opening Balance	1,101.1	1,154.2
Total comprehensive income for the period	-20.4	-1.6
<b>Total change excluding owner transactions</b>	<b>1,080.7</b>	<b>1,152.6</b>
<b>Equity at the end of the period</b>	<b>1,080.7</b>	<b>1,152.6</b>
Attributable to equity holders of the parent company	1,080.7	1,152.6
Non-controlling interest	N/A	N/A

## Consolidated cashflow statement

<b>MSEK</b>	<b>Jan-Jun 2021</b>	<b>Jan-Jun 2020</b>
Income after financial items	-21.8	4.2
Adjusted for non-cash items	87.8	76.6
Taxes paid	-11.3	
Changes in working capital	-273.4	-176.5
<b>Cash flow from operating activities</b>	<b>-218.7</b>	<b>-95.7</b>
Investments in intangibles/tangibles	-24.5	-16.9
<b>Cashflow from investing activities</b>	<b>-26.5</b>	<b>-16.9</b>
Lease payments	-6.0	-9.3
<b>Cashflow from financing activities</b>	<b>-6.0</b>	<b>-9.3</b>
<b>Changes in cash and cash equivalents</b>	<b>-251.2</b>	<b>-121.9</b>
<b>Opening cash and cash equivalents balance</b>	<b>398.5</b>	<b>337.1</b>
<b>Cash and cash equivalents by end of the period</b>	<b>147.3</b>	<b>215.2</b>

Since the structure in the interim report differs from the annual report, in the table below the year to date consolidated income statement is shown in the annual report format.

## Consolidated Income Statement – Annual report format

<b>MSEK</b>	<b>Jan-Jun 2021</b>	<b>Jan-Jun 2020</b>
Net sales	366.9	335.7
Other revenue	35.6	24.6
Capitalized R&D	29.1	14.5
<b>Total</b>	<b>431.6</b>	<b>374.8</b>
Other external expenses	-133.9	-86.7
Personnel cost	-234.3	-198.8
Depreciation	-75.3	-71.8
<b>Operating income</b>	<b>-11.9</b>	<b>17.5</b>
Financial net	-9.9	-13.3
<b>Income before tax</b>	<b>-21.8</b>	<b>4.2</b>
Tax	2.6	-1.4
<b>Net Income</b>	<b>-19.2</b>	<b>2.8</b>

## Segment reporting

The group recognizes only a single segment in accordance with the definition of operating segment in IFRS 8. The starting point for identifying operating segments on which separate information can be provided are the internal reports to and monitoring by the group management. The group management monitors operating income for the entire business as one operating segment.

## Timing of revenue

<b>MSEK</b>	<b>Q2 2021</b>	<b>Q2 2020</b>
Timing of revenue recognition		
At a point in time	84.8	81.4
Over time	111.0	101.0
	<b>195.8</b>	<b>182.4</b>

"At a point in time" is defined as revenue correlated to working hours while "over time" is not.

## Intangible assets

<b>MSEK</b>	<b>Capitalised development expenditure</b>	<b>Customer contracts/ accrued revenues</b>	<b>Trademarks</b>	<b>Technology</b>	<b>Goodwill</b>	<b>Total</b>
At 31 Dec 2020	107.4	536.4	88.2	849.4	467.6	2,049.0
Acquisitions for the period	18.7					18.7
Depreciation for the period	-8.1	-21.8		-33.3		-63.2
Exchange rate changes				0.9		0.9
<b>At 30 Jun 2021</b>	<b>118.0</b>	<b>514.6</b>	<b>88.2</b>	<b>817.0</b>	<b>467.6</b>	<b>2,005.4</b>

## APPLICABLE ACCOUNTING RULES

Sanolium AB complies with IFRS standards and interpretations (IFRIC) as adopted by the EU. This Interim Report has been prepared in accordance with IAS 34 Interim Financial Reporting. The Parent Company's financial statements have been prepared in accordance with RFR 2. The accounting policies applied are consistent with those presented in the Annual Report for 2019, except for the adoption of standard amendments effective as of January 1, 2021. The amendments are not expected to have any material impact on the financial statements.

Detailed information about the Group's accounting and valuation principles can be found in the Annual Report for 2020 which is available on [www.cambio.se](http://www.cambio.se).

This interim report refers to certain key performance indicators which Cambio and others use when evaluating the performance of Cambio. These are referred to as alternative performance measures (APMs) and are not defined under IFRS. The figures give management and investors important information and enable both to analyze Cambio's business and trends. The APMs are not meant to replace but to complement the performance measures defined under IFRS.

## Parent company

Sanolium AB is a holding company that invests in fast-growing companies within the e-health industry. The company is one of the largest e-Health companies in Northern Europe and has the ambition to grow faster than the market through organic opportunities as well as acquisitions. This should be done in a profitable and sustainable manner. Sanolium AB's operational subsidiaries' vision is to enable tomorrow's healthcare today.

The operating entities mainly deliver products and services in Sweden under the names Cambio COSMIC and Cambio VIVA.

Sanolium AB has no employees.

## Income Statement Parent Company

MSEK	Q2 2021	Q2 2020	Jan-Jun 2021	Jan-Jun 2020
Other revenue		2.9	2.5	2.9
<b>Revenue</b>		<b>2.9</b>	<b>2.5</b>	<b>2.9</b>
Employee related expenses		-2.7	-2.4	-2.8
<b>Total operating expenses</b>	<b>-1.0</b>	<b>-2.7</b>	<b>-3.4</b>	<b>-2.8</b>
<b>Adjusted EBITDA</b>	<b>-1.0</b>	<b>0.2</b>	<b>-0.9</b>	<b>0.1</b>
Non recurring items		-0.2	-0.3	-0.8
<b>EBIT</b>	<b>-1.0</b>	<b>-0.0</b>	<b>-1.2</b>	<b>-0.7</b>
Financial net	-5.7	-7.4	-11.7	-13.4
<b>Net Income</b>	<b>-6.7</b>	<b>-7.4</b>	<b>-12.9</b>	<b>-14.1</b>



## Balance sheet Parent Company

<b>MSEK</b>	<b>2021-06-30</b>	<b>2020-12-31</b>
<i>Fixed Assets</i>		
Financial assets	1,814.4	1,814.8
<b>Total Fixed Assets</b>	<b>1,814.4</b>	<b>1,814.8</b>
<i>Current Assets</i>		
Other receivables	0.2	0.1
Other receivables - Group	10.5	7.4
Prepaid expenses and accrued income	0.1	0.2
Cash	5.4	6.1
<b>Total Current Assets</b>	<b>16.2</b>	<b>13.8</b>
<b>Total Assets</b>	<b>1,830.6</b>	<b>1,828.6</b>
<i>Equity</i>		
Share capital	1.7	1.7
Non-restricted equity	1,187.4	1,215.2
Net income for the year	-12.9	-27.8
<b>Total Equity</b>	<b>1,176.2</b>	<b>1,189.1</b>
<b>Total Financial Liabilities</b>	<b>497.9</b>	<b>497.6</b>
<i>Other liabilities</i>		
Other liabilities	104.9	99.4
Other liabilities - Group	51.5	42.0
Accrued expenses	0.1	0.5
<b>Total Other Liabilities</b>	<b>156.5</b>	<b>141.9</b>
<b>Total Equity and Liabilities</b>	<b>1,830.6</b>	<b>1,828.6</b>

## Changes in Parent company equity

<b>MSEK</b>	<b>Jan-Jun 2021</b>	<b>Jan-Jun 2020</b>
Opening Balance	1,182.9	1,210.2
Total comprehensive income for the period	-6.7	-7.4
<b>Total change excluding owner transactions</b>	<b>1,176.2</b>	<b>1,202.8</b>
<b>Equity at the end of the period</b>	<b>1,176.2</b>	<b>1,202.8</b>
Attributable to equity holders of the parent company	1,176.2	1,202.8
Non-controlling interest	N/A	N/A

## Parent company cash flow

<b>MSEK</b>	<b>Jan-Jun 2021</b>	<b>Jan-Jun 2020</b>
Income after financial items	-12.9	-14.2
Changes in working capital	12.2	9.3
<b>Cash flow from operating activities</b>	<b>-0.7</b>	<b>-4.9</b>
<b>Changes in cash and cash equivalents</b>	<b>-0.7</b>	<b>-4.9</b>
<b>Opening cash and cash equivalents balance</b>	<b>6.1</b>	<b>10.8</b>
<b>Cash and cash equivalents by end of the period</b>	<b>5.4</b>	<b>5.9</b>

## Definitions

### Adjusted EBIT

Income before non recurring items, financial net and tax.

### Adjusted EBITDA

Income before depreciation, non-recurring items, financial net and tax.

### Adjusted EBITDA margin

Adjusted EBITDA as a percentage of revenue.

### Cash conversion

Operating cash flow divided by adjusted EBITDA.

### EBIT

Income before financial net and tax.

### Non-recurring items

Items excluded from the normal operating items e.g restructuring costs, costs related to introduction of a new ERP system, M&A related costs and costs regarding refinancing or to set a financing structure (excluding interest on external debt).

### Operating cash flow

Adjusted EBITDA minus capital expenditures, capitalized R&D and net working capital changes.



### ***Financial calendar***

Annual General Meeting, 2021-05-04  
Interim report Q3 January-September, 2021-11-30  
Interim report Q4 January-December, 2022-02-28



### ***Presentation of the interim report***

Cambio's interim reports will be published at [cambiogroup.com](http://cambiogroup.com) at each of the dates stipulated above.

### ***Information***

For further information, please contact:  
Fredrik Rüdén, CFO +46 760 018 422  
[fredrik.ruden@cambio.se](mailto:fredrik.ruden@cambio.se)



### ***Sanolium AB***

Cambio Healthcare Systems AB  
Drottninggatan 89  
113 60 Stockholm

+46 8 691 49 00  
[info@cambio.se](mailto:info@cambio.se)

